Cargando…
Cancer drugs, survival and ethics: a critical look from the inside
Autores principales: | Piccart, Martine, Pondé, Noam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
ESMO Open
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419213/ https://www.ncbi.nlm.nih.gov/pubmed/28848670 http://dx.doi.org/10.1136/esmoopen-2016-000149 |
Ejemplares similares
-
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019) -
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019) -
Threat posed by unproven drugs in medical oncology
por: Pondé, Noam, et al.
Publicado: (2016) -
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
por: Caparica, Rafael, et al.
Publicado: (2019) -
A Look Inside of the Complex Pathogenesis of B-RAF(V600E)-Driven Cancer
por: Caputo, Emilia
Publicado: (2017)